Sup. Figure 4: Foretinib and nintedanib inhibited p TRK-A in KM12SM-ER cells more efficiently than that in KM12SM cells. from Foretinib Overcomes Entrectinib Resistance Associated with the &lt;i&gt;NTRK1&lt;/i&gt; G667C Mutation in &lt;i&gt;NTRK1&lt;/i&gt; Fusion–Positive Tumor Cells in a Brain Metastasis Model